Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for BCPC and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for BCPC and 80,000+ other tickers.
See exactly how BCPC's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BCPC and 80,000+ other tickers.
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems…
Balchem posted strong sales growth of 8.6% during the quarter and free cash flow of $57.9 million. BCPC's business is great—growing earnings, low borrowings, and continuous share buybacks. My DCF valuation states the stock should be priced at roughly $88. The current price of $177 reflects an overvaluation of roughly 50%.
Third-quarter net sales rose 8.6% year over year to $291 million. Human nutrition and health segment sales increased 8.1% to $188 million.
Balchem Corporation (BCPC) Q3 2026 Earnings Call Transcript
MONTVALE, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today reported financial results for its 2026 fiscal third quarter ended September 30, 2026.
MONTVALE, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Friday, October 23, 2026, at 11:00 AM Eastern Time (ET) to review third quarter results.